{"id":17360,"date":"2024-02-06T14:56:08","date_gmt":"2024-02-06T19:56:08","guid":{"rendered":"https:\/\/www.ices.on.ca\/?post_type=private_project&#038;p=17360"},"modified":"2025-02-28T09:16:10","modified_gmt":"2025-02-28T14:16:10","slug":"incidence-and-risk-quantification-of-herpes-zoster-shingles-infections","status":"publish","type":"private_project","link":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/incidence-and-risk-quantification-of-herpes-zoster-shingles-infections\/","title":{"rendered":"Incidence and risk quantification of Herpes Zoster (shingles) infections in people with autoimmune diseases or other comorbidities in Ontario"},"content":{"rendered":"<p><strong>Client:<\/strong> IQVIA Solutions Canada Inc.<\/p>\n<p><strong>Project ID:<\/strong> P2022-149\/ 2024 0970 365 000<\/p>\n<p><strong>Research Question\/Objectives:<\/strong> The objective of this study is to better understand the incidence and risk factors of developing HZ and PHN in the adult population (18+) in Ontario.<\/p>\n<p><strong>Objectives:<\/strong><\/p>\n<p><em>Primary objectives:<\/em><br \/>\n1. Estimate the annual incidence of HZ in the general adult (18+) Ontario population<br \/>\n2. Estimate the annual incidence of HZ among adults (18+) with AID or comorbidities in Ontario. The following are the AIDs and comorbidities of interest:<\/p>\n<ul>\n<li>AIDs<\/li>\n<\/ul>\n<p style=\"padding-left: 80px;\">o Rheumatoid arthritis (RA)<br \/>\no Systemic lupus erythematosus (SLE)<br \/>\no Inflammatory bowel disease (IBD)<br \/>\no Psoriatic arthritis (PsA)<br \/>\no Multiple sclerosis (MS)<\/p>\n<ul>\n<li>\u00a0Comorbidities<\/li>\n<\/ul>\n<p style=\"padding-left: 80px;\">o Diabetes<br \/>\no Asthma<br \/>\no Chronic obstructive pulmonary disease (COPD)<br \/>\no Chronic kidney disease (CKD)<br \/>\no Cardiovascular disease (CVD)<br \/>\no Cerebrovascular disease<\/p>\n<p><em>Secondary objectives:<\/em><\/p>\n<ol>\n<li>Estimate the proportion of HZ patients in the general adult (18+) Ontario population who develop PHN<\/li>\n<li>Estimate the proportion of HZ patients among adults with AID in Ontario who develop PHN<\/li>\n<li>Estimate the proportion of HZ<\/li>\n<\/ol>\n<p><em>Exploratory objectives:<\/em><\/p>\n<p>Risk Factors<\/p>\n<ol>\n<li>Estimate the multivariable associations between risk factors and the incidence of HZ amongst those with AID\/comorbid conditions.<\/li>\n<\/ol>\n<p>Healthcare Resource Utilization<\/p>\n<ol>\n<li>To describe the HCRU and direct healthcare costs among the general adult (18+) Ontario population with HZ<\/li>\n<li>To describe the HCRU and direct healthcare costs among general adult (18+) Ontario population whose HZ developed into PHN<\/li>\n<li>To describe the HCRU and direct healthcare costs among individuals with AID or comorbid with HZ<\/li>\n<li>To describe the HCRU and direct healthcare costs among individuals with AID or comorbidities whose HZ developed into PHN<\/li>\n<li>To compare differences in direct healthcare costs and HCRU among the general adult Ontario population with HZ (Population A-2, see Section 7.2) as well as among individuals with AID or specific comorbidities and HZ (Population B-2) with their respective controls that do not have HZ (Populations A-1 and B-1, respectively), matched using propensity score.<\/li>\n<\/ol>\n<p><strong>Status:<\/strong> Completed<\/p>\n<p><strong>Results:<\/strong> July 2025<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Client: IQVIA Solutions Canada Inc. Project ID: P2022-149\/ 2024 0970 365 000 Research Question\/Objectives: The objective of this study is to better understand the incidence and risk factors of developing HZ and PHN in the adult population (18+) in Ontario. Objectives: Primary objectives: 1. Estimate the annual incidence of HZ in the general adult (18+) [&hellip;]<\/p>\n","protected":false},"template":"","organization_type":[],"project_status":[105],"response_type":[],"class_list":["post-17360","private_project","type-private_project","status-publish","hentry","project_status-completed"],"acf":{"project_id":"P2022-149\/ 2024 0970 365 000","project_id_year":2023,"ices_scientist":"","principal_investigators":null,"knowledge_user":"","client":"","objectives":"","results":"","availability_of_results":"","pia_approved":null,"infographic":"","sitecore_item_id":"","sitecore_item_name":"","sitecore_field_values":""},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Incidence and risk quantification of Herpes Zoster (shingles) infections in people with autoimmune diseases or other comorbidities in Ontario | ICES<\/title>\n<meta name=\"description\" content=\"Client: IQVIA Solutions Canada Inc. Project ID: P2022-149\/ 2024 0970 365 000 Research Question\/Objectives: The objective of this study is to better\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/incidence-and-risk-quantification-of-herpes-zoster-shingles-infections\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Incidence and risk quantification of Herpes Zoster (shingles) infections in people with autoimmune diseases or other comorbidities in Ontario | ICES\" \/>\n<meta property=\"og:description\" content=\"Client: IQVIA Solutions Canada Inc. Project ID: P2022-149\/ 2024 0970 365 000 Research Question\/Objectives: The objective of this study is to better\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/incidence-and-risk-quantification-of-herpes-zoster-shingles-infections\/\" \/>\n<meta property=\"og:site_name\" content=\"ICES\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ICESOntario\/\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-28T14:16:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2024\/11\/ic-es-data-discovery-better-health-logo.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/services-for-researchers\\\/all-projects\\\/private-sector-projects\\\/incidence-and-risk-quantification-of-herpes-zoster-shingles-infections\\\/\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/services-for-researchers\\\/all-projects\\\/private-sector-projects\\\/incidence-and-risk-quantification-of-herpes-zoster-shingles-infections\\\/\",\"name\":\"Incidence and risk quantification of Herpes Zoster (shingles) infections in people with autoimmune diseases or other comorbidities in Ontario | ICES\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#website\"},\"datePublished\":\"2024-02-06T19:56:08+00:00\",\"dateModified\":\"2025-02-28T14:16:10+00:00\",\"description\":\"Client: IQVIA Solutions Canada Inc. Project ID: P2022-149\\\/ 2024 0970 365 000 Research Question\\\/Objectives: The objective of this study is to better\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/services-for-researchers\\\/all-projects\\\/private-sector-projects\\\/incidence-and-risk-quantification-of-herpes-zoster-shingles-infections\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/services-for-researchers\\\/all-projects\\\/private-sector-projects\\\/incidence-and-risk-quantification-of-herpes-zoster-shingles-infections\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/services-for-researchers\\\/all-projects\\\/private-sector-projects\\\/incidence-and-risk-quantification-of-herpes-zoster-shingles-infections\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Private Sector Projects\",\"item\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/services-for-researchers\\\/all-projects\\\/private-sector-projects\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Incidence and risk quantification of Herpes Zoster (shingles) infections in people with autoimmune diseases or other comorbidities in Ontario\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\",\"name\":\"ICES\",\"description\":\"POPULATION-BASED HEALTH RESEARCH THAT MAKES A DIFFERENCE\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#organization\"},\"alternateName\":\"Institute for Clinical Evaluative Sciences\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#organization\",\"name\":\"ICES\",\"alternateName\":\"Institute for Clinical Evaluative Sciences\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/ices-logo.png\",\"contentUrl\":\"https:\\\/\\\/www.ices.on.ca\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/ices-logo.png\",\"width\":\"676\",\"height\":\"618\",\"caption\":\"ICES\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/ICESOntario\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ices-research-institute\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Incidence and risk quantification of Herpes Zoster (shingles) infections in people with autoimmune diseases or other comorbidities in Ontario | ICES","description":"Client: IQVIA Solutions Canada Inc. Project ID: P2022-149\/ 2024 0970 365 000 Research Question\/Objectives: The objective of this study is to better","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/incidence-and-risk-quantification-of-herpes-zoster-shingles-infections\/","og_locale":"fr_FR","og_type":"article","og_title":"Incidence and risk quantification of Herpes Zoster (shingles) infections in people with autoimmune diseases or other comorbidities in Ontario | ICES","og_description":"Client: IQVIA Solutions Canada Inc. Project ID: P2022-149\/ 2024 0970 365 000 Research Question\/Objectives: The objective of this study is to better","og_url":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/incidence-and-risk-quantification-of-herpes-zoster-shingles-infections\/","og_site_name":"ICES","article_publisher":"https:\/\/www.facebook.com\/ICESOntario\/","article_modified_time":"2025-02-28T14:16:10+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2024\/11\/ic-es-data-discovery-better-health-logo.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/incidence-and-risk-quantification-of-herpes-zoster-shingles-infections\/","url":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/incidence-and-risk-quantification-of-herpes-zoster-shingles-infections\/","name":"Incidence and risk quantification of Herpes Zoster (shingles) infections in people with autoimmune diseases or other comorbidities in Ontario | ICES","isPartOf":{"@id":"https:\/\/www.ices.on.ca\/fr\/#website"},"datePublished":"2024-02-06T19:56:08+00:00","dateModified":"2025-02-28T14:16:10+00:00","description":"Client: IQVIA Solutions Canada Inc. Project ID: P2022-149\/ 2024 0970 365 000 Research Question\/Objectives: The objective of this study is to better","breadcrumb":{"@id":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/incidence-and-risk-quantification-of-herpes-zoster-shingles-infections\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/incidence-and-risk-quantification-of-herpes-zoster-shingles-infections\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/incidence-and-risk-quantification-of-herpes-zoster-shingles-infections\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ices.on.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Private Sector Projects","item":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/"},{"@type":"ListItem","position":3,"name":"Incidence and risk quantification of Herpes Zoster (shingles) infections in people with autoimmune diseases or other comorbidities in Ontario"}]},{"@type":"WebSite","@id":"https:\/\/www.ices.on.ca\/fr\/#website","url":"https:\/\/www.ices.on.ca\/fr\/","name":"ICES","description":"POPULATION-BASED HEALTH RESEARCH THAT MAKES A DIFFERENCE","publisher":{"@id":"https:\/\/www.ices.on.ca\/fr\/#organization"},"alternateName":"Institute for Clinical Evaluative Sciences","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ices.on.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ices.on.ca\/fr\/#organization","name":"ICES","alternateName":"Institute for Clinical Evaluative Sciences","url":"https:\/\/www.ices.on.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ices.on.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2023\/04\/ices-logo.png","contentUrl":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2023\/04\/ices-logo.png","width":"676","height":"618","caption":"ICES"},"image":{"@id":"https:\/\/www.ices.on.ca\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ICESOntario\/","https:\/\/www.linkedin.com\/company\/ices-research-institute\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/private_project\/17360","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/private_project"}],"about":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/types\/private_project"}],"wp:attachment":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/media?parent=17360"}],"wp:term":[{"taxonomy":"organization_type","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/organization_type?post=17360"},{"taxonomy":"project_status","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/project_status?post=17360"},{"taxonomy":"response_type","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/response_type?post=17360"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}